It looks like you're using an ad blocker.

To enjoy our content, please include The Japan Times on your ad-blocker's list of approved sites.

Thank you for supporting our journalism.

  • HOME DELIVERY |
  • SUBSCRIBE |
  • Login
  • My Account
TODAY'S PRINT EDITION

The Japan Times The Japan Times

medicine

  • Login
  • SUBSCRIBE
  • My Account
  • HOME DELIVERY ≫
  • (FREE ARTICLE)
  • MENU
  • Search
  • News
  • Opinion
  • Life
  • Community
  • Culture
  • Sports
  • City Guide
  • Support
  • Search
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
COVID cases in Tokyo hit 471,000 as of March — quadruple official tally — study says

National Nov 13, 2021

COVID cases in Tokyo hit 471,000 as of March — quadruple official tally — study says

by Osamu Tsukimori

Researchers say asymptomatic or mild cases likely behind dramatic undercount in number of coronavirus infections.

Why COVID-19 misinformation works

Commentary / World Nov 12, 2021

Why COVID-19 misinformation works

by Noam Titelman

Misinformed people, especially about COVID-19, do not simply have inaccurate information; they are heavily invested in their misconceptions.

Regeneron antibody prevents COVID-19 infections for eight months

World Nov 9, 2021

Regeneron antibody prevents COVID-19 infections for eight months

by Elaine Chen

The company has asked the U.S. Food and Drug Administration to expand the authorization so the drug can be used to prevent infections.

COVID-19 pills no substitute for vaccines, disease experts say

World | ANALYSIS Nov 9, 2021

COVID-19 pills no substitute for vaccines, disease experts say

by Julie Steenhuysen

Some experts fear the arrival of oral treatments for the coronavirus may further impede vaccination campaigns.

South Korea to purchase 70,000 courses of new Pfizer COVID-19 pill

Asia Pacific Nov 8, 2021

South Korea to purchase 70,000 courses of new Pfizer COVID-19 pill

Pfizer has said trial results showed that its Paxlovid pill reduced by 89% the risk of hospitalization or death in some patients.

COVID-19 drugs will change the way we live with the virus

Commentary / World Nov 7, 2021

COVID-19 drugs will change the way we live with the virus

by Therese Raphael

New COVID-19 drug approvals couldn’t be timelier as hospitals face massive backlogs of delayed procedures.

Pfizer results open door to new chapter for COVID treatments

World / Science & Health | ANALYSIS Nov 6, 2021

Pfizer results open door to new chapter for COVID treatments

by Emma Court and Fiona Rutherford

The world needs an easy-to-take COVID-19 treatment. Pfizer Inc.’s and Merck & Co. Inc.’s new pills may be just that. But questions remain about their safety and how well they will work.

Pfizer develops COVID-19 pill that cuts hospitalizations and deaths by 89%

World / Science & Health Nov 5, 2021

Pfizer develops COVID-19 pill that cuts hospitalizations and deaths by 89%

by Robert Langreth

The drugmaker claims "overwhelming efficacy” and plans to submit their findings for emergency authorization as soon as possible.

Lessons ASEAN could learn from Malaysia’s pandemic success

Commentary / World Nov 5, 2021

Lessons ASEAN could learn from Malaysia’s pandemic success

by Joshua Kurlantzick

Malaysia has fully vaccinated more than 77% its population, with some 90% of adults — those deemed eligible for the vaccine — receiving a second dose.

Post-pandemic recovery must include the unpaid care economy

Commentary Nov 3, 2021

Post-pandemic recovery must include the unpaid care economy

by Mercedes D’alessandro and Maria S. Floro

The unpaid care sector for the most part remains unaccounted for in standard government policy tools and its work is primarily performed by women.

How often do COVID-19 vaccines cause heart problems in kids?

World / Science & Health Nov 2, 2021

How often do COVID-19 vaccines cause heart problems in kids?

by Apoorva Mandavilli

While the vaccines made by Pfizer-BioNTech and Moderna do seem to be associated with an increased risk of myocarditis, the absolute risk remains very small.

Pfizer won the first round, but Moderna sees final victory ahead

World Oct 30, 2021

Pfizer won the first round, but Moderna sees final victory ahead

by Robert Langreth and Riley Griffin

Pfizer has been first across the finish line in nearly every leg of the COVID-19 vaccine race, but Moderna executives say their company’s mRNA technology gives it an advantage.

« 1 … 22 23 24 … 46 »
  • WHAT’S TRENDING
  • EDITORS’ PICKS
  • Nadeshiko Japan downs Costa Rica to move into knockout stage

    Thumbnail image
  • AI is rewriting the rules of $200 billion games industry

    Thumbnail image
  • Indonesia rides EV rush to domestic IPO boom

    Thumbnail image
  • 'Japan's Anatolia' becomes a home away from home for Kurds and Turks

    Thumbnail image
  • From 'Young General' to 'Supreme Leader': The evolution of Kim Jong Un

    Thumbnail image

PODCAST

  • DEEP DIVE

    A tale of two Fujis: Bullet climbs, crowds and Lizzo

Return to The Japan Times top page
JT Digital Archives The Japan Times Alpha JT Bookclub The Japan Times Jobs Education in Japan
  • SUBSCRIBE
  • NEWSLETTERS
  • ePaper Edition
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
  • About us
  • Contact us
  • Work with us
  • Privacy Policy
  • Link policy
  • Republishing
  • FAQs
  • Announcements
  • Press
  • Sitemap
  • Advertise

The Japan Times LTD. All rights reserved.

The Japan Times